Floatz logo

Vosaroxin

Myelodysplastic Syndromes

Cardiff UniversitySmall moleculePhase 2/3Dormant
B
61/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
59/ 100
Competitive Position
65/ 100

Competitive context

315 Active assets in the Myelodysplastic Syndromes cohort.

Asset / SponsorPhaseRating
Fludarabine
Sawa Ito, MD
Phase 4BB
Daunorubicin
OHSU Knight Cancer Institute
Phase 3BB
FILGRASTIM
City of Hope Medical Center
Phase 4BB
Cyclophosphamide
Sawa Ito, MD
Phase 4BB
Cytosin-Arabinosid
The First Affiliated Hospital of Soochow University
Phase 4BB

View all 50 →

Same molecule, other indications

Vosaroxin is also rated in:

acute myeloid leukemiaDormant
BB
Indicative ·
66 / 100
View asset →
leukemiaDormant
B
Indicative ·
58 / 100
View asset →
acute myeloid leukemia with multilineage dysplasiaDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →